New old drug fights colon cancer

Oct 13, 2009

A new Tel Aviv University drug, based on an older generation antibiotic, may provide doctors with an effective and innovative method of treating colon cancer in both its incipient and full-blown stages -- and minimize the need for painful, uncomfortable colonoscopies and surgical polyp removal.

Dr. Rina Rosin-Arbesfeld of TAU's Sackler School of Medicine has shown in preclinical studies that a common antibiotic can suppress the growth of polyps in mice. Her aim is to reformulate the drug for use as a preventative therapy -- or, in stronger doses, in combination with chemotherapy and radiation to fight existing cancers until they're gone. The current formulation reduced the size of the polyps in about 80% of the mice she studied, and on average the animals lived 30% longer than those who were not given the antibiotic.

"My experience shows that colon cancer is particularly aggressive," says Dr. Rosin-Arbesfeld. "Our new drug may be able to slow down polyp growth so that it never manifests to full-blown colon cancer." She is currently preparing the results of her recent study for an upcoming issue of the journal Gut.

Taking genes to the repair shop

The antibiotic acts in a genetic fashion. In diseases like (CF) and , from the aminiglycoside family can repair damaged or mutated DNA. For her new study, Dr. Rosin-Arbesfeld looked at a closely-related but less toxic family of antibiotics from the Macrolide family that achieves the same therapeutic results.

Dr. Rosin-Arbesfeld focused on a gene associated with colorectal cancer, the APC gene, and noticed that the mutation types in colorectal cancer are similar to those in the CF gene. Noting that old generation antibiotics are effective in fighting CF, she studied its effects on colon cancer as well. She found that the drug partially repaired faulty genes in mice with colon cancer. Benefits from using old generation and out of circulation antibiotics means that the new therapy will not interfere with current antibiotics used for today's bacterial infections.

At first she thought about using the antibiotic as a preventative therapy, but later investigated its efficacy in treating full-blown cancer and found it similarly effective.

A fast track to getting the drug to market

Ramot, TAU's commercial transfer company, has filed for a patent for the new use, and because the antibiotic has already been on the market, Dr. Rosin-Arbesfeld expects the new drug could be developed quickly. The preclinical results are encouraging and Ramot is currently talking with potential partners to bring this drug to experimental trials in humans, a critical step before it can be made more widely available.

"For many years it's been known that a specific family of antibiotics does more than kill bacteria," says Dr. Rosin-Arbesfeld. "They affect biological systems in the body and repair mutated genes. In directing my work towards the treatment of cancer, I can help save lives."

Source: Tel Aviv University (news : web)

Explore further: Death rates from pancreatic cancer predicted to rise in Europe in 2014

add to favorites email to friend print save as pdf

Related Stories

A simple blood test for colon cancer

Nov 20, 2008

People are often reluctant to undergo a routine but painful colonoscopy -- but the consequences can be fatal. According to the American Cancer Society, colon cancer is the third most common cancer found in American men ...

Not just for depression anymore

Dec 18, 2008

Prozac is regularly prescribed to ease the emotional pain of patients who are being treated for cancer. But can this common anti-depressant help to fight cancer itself?

New function for colon cancer gene found

Jan 17, 2008

Dartmouth Medical School geneticists have discovered a striking turnabout role for a gatekeeper known to put on the brakes for colon cancer. Flaws in a gene called adenomatous polyposis coli (APC), which normally prevents ...

Recommended for you

Phase 3 study may be game-changer for acute myeloid leukemia

2 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments : 0

More news stories

FDA proposes first regulations for e-cigarettes

The federal government wants to prohibit sales of electronic cigarettes to minors and require approval for new products and health warning labels under regulations being proposed by the Food and Drug Administration.

Rising role seen for health education specialists

(HealthDay)—A health education specialist can help family practices implement quality improvement projects with limited additional financial resources, according to an article published in the March/April ...

When things get glassy, molecules go fractal

Colorful church windows, beads on a necklace and many of our favorite plastics share something in common—they all belong to a state of matter known as glasses. School children learn the difference between ...

FCC to propose pay-for-priority Internet standards

The Federal Communications Commission is set to propose new open Internet rules that would allow content companies to pay for faster delivery over the so-called "last mile" connection to people's homes.

SK Hynix posts Q1 surge in net profit

South Korea's SK Hynix Inc said Thursday its first-quarter net profit surged nearly 350 percent from the previous year on a spike in sales of PC memory chips.